Literature DB >> 26449505

Burden of serious fungal infections in Mexico.

D E Corzo-León1, D Armstrong-James2,3, D W Denning4.   

Abstract

Serious fungal infections (SFIs) could be more frequent than are recognised. Estimates of the incidence and prevalence of SFIs are essential in order to identify public health problems. We estimated the rates of SFIs in Mexico, following a methodology similar to that used in prior studies. We obtained information about the general population and populations at risk. A systematic literature search was undertaken to identify epidemiological reports of SFIs in Mexico. When Mexican reports were unavailable, we based our estimates on international literature. The most prevalent SFIs in Mexico are recurrent vulvovaginal candidiasis (5999 per 100,000) followed by allergic bronchopulmonary aspergillosis (60 per 100,000), chronic pulmonary aspergillosis (15.9 per 100,000), fungal keratitis (10.4 per 100,000), invasive candidiasis (8.6 per 100,000) and SFIs in HIV (8.2 per 100,000); coccidioidomycosis (7.6 per 100,000), IA (4.56 per 100,000). These correspond to 2,749,159 people affected in any year (2.45% of the population), probably >10,000 deaths and 7000 blind eyes. SFIs affect immunocompromised and healthy populations. Most are associated with high morbidity and mortality rates. Validation of these estimates with epidemiological studies is required. The burdens indicate that an urgent need to improve medical skills, surveillance, diagnosis, and management of SFIs exists.
© 2015 Blackwell Verlag GmbH.

Entities:  

Keywords:  Epidemiology; Mexico; aspergillosis; burden; fungal infection

Mesh:

Year:  2015        PMID: 26449505     DOI: 10.1111/myc.12395

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  14 in total

Review 1.  Exploiting mitochondria as targets for the development of new antifungals.

Authors:  Dongmei Li; Richard Calderone
Journal:  Virulence       Date:  2016-05-18       Impact factor: 5.882

2.  Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.

Authors:  Leighann Sherry; Ryan Kean; Emily McKloud; Lindsay E O'Donnell; Rebecca Metcalfe; Brian L Jones; Gordon Ramage
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Immune Response to Coccidioidomycosis and the Development of a Vaccine.

Authors:  Natalia Castro-Lopez; Chiung-Yu Hung
Journal:  Microorganisms       Date:  2017-03-16

Review 4.  Update on invasive fungal infections in the Middle Eastern and North African region.

Authors:  Marwan Osman; Aisha Al Bikai; Rayane Rafei; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  Braz J Microbiol       Date:  2020-07-05       Impact factor: 2.476

5.  Influenza challenging the diagnosis and management of pulmonary coccidioidomycosis.

Authors:  Luis David Chora-Hernández; Beatriz Sereno-Gómez; Francisco Ruiz-Martínez; Juan Manuel Barajas-Magallon; Miguel Ruiz-Jiménez; Dora E Corzo-Leon
Journal:  Med Mycol Case Rep       Date:  2020-07-17

Review 6.  Histoplasmosis in Africa: An emerging or a neglected disease?

Authors:  Rita O Oladele; Olusola O Ayanlowo; Malcolm D Richardson; David W Denning
Journal:  PLoS Negl Trop Dis       Date:  2018-01-18

Review 7.  Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision.

Authors:  Felix Bongomin; Sara Gago; Rita O Oladele; David W Denning
Journal:  J Fungi (Basel)       Date:  2017-10-18

8.  New insights into the clinical characteristics and prognostic factors of pulmonary fungal infections from a retrospective study in Southwestern China.

Authors:  Li Peng; Zhiping Xu; Zhenyu Huo; Rui Long; Liang Ma
Journal:  Infect Drug Resist       Date:  2018-03-05       Impact factor: 4.003

9.  Burden of Serious Fungal Infections in Jordan.

Authors:  Jamal Wadi; David W Denning
Journal:  J Fungi (Basel)       Date:  2018-01-18

Review 10.  Re-drawing the Maps for Endemic Mycoses.

Authors:  Nida Ashraf; Ryan C Kubat; Victoria Poplin; Antoine A Adenis; David W Denning; Laura Wright; Orion McCotter; Ilan S Schwartz; Brendan R Jackson; Tom Chiller; Nathan C Bahr
Journal:  Mycopathologia       Date:  2020-02-10       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.